H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on MoonLake Immunotherapeutics to $30 from $28 and keeps a Buy rating on the shares. The analyst continues to expect positive sonelokimab Phase 2 data in the near-term.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MLTX:
- MoonLake Immunotherapeutics management to meet with Piper Sandler
- MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
- Cantor biopharma/biotech analysts hold analyst/industry conference call
- This Insider Just Pocketed MoonLake (NASDAQ:MLTX) Stock Worth $16.8M
- Wedbush bullish on MoonLake Immunotherapeutics, initiates with an Outperform
